ST98032.ST25.txt SEQUENCE LISTING

. .

```
<110> Aventis Pharma S.A.
<120> Use Of Specific Hybrid Promoters For Controlling Tissue Express
ion
<130> ST98032
<150> US 60/123298
<151> 1999-04-04
<150> FR/98/12000
<151> 1998-09-25
<160> 10
<170> PatentIn version 3.0
<210> 1
<211> 23
<212> DNA
<213> Artificial
₹220>
<223> Artificial Sequence
<220>
<221> nucleotide
<222> (1)..(23)
<400> 1
gatggtccct acttatgctg cta
23
<210> 2
<211> 23
<212> DNA
<213> Artificial
<220>
<223> articifial sequence
<220>
<221> nucleotide
<222> (1)..(23)
```

```
ST98032.ST25.txt
<400> 2
cttccatcat accaaactac ata
23
<210> 3
<211> 32
<212> DNA
<213> Artificial
<220>
<223> artificial sequence
<220>
<221> nucleotide
<222> (1)..(32)
<400> 3
ctgctaaatt gctcgaggac aaattagaca aa
32
<210> 4
<211> 33
<212> DNA
<213> Artificial
<220>
<223> artificial sequence
<220>
<221> oligonucleotide
<222> (1)..(33)
<400> 4
ccctgacaaa gcttggctgg gctgctccac tgg
33
<210> 5
<211> 30
<212> DNA
<213> Artificial
<220>
<223> artificial sequence
<220>
```

. .

Page 2

```
ST98032.ST25.txt
<221> oligonucleotide
<222> (1)..(30)
<400> 5
atcgacgcgt gcccgttaca taacttacgg
<210> 6
<211> 38
<212> DNA
<213> Artificial
<220>
<223> artificial sequence
<220>
<221> oligonucleotide
<222> (1)..(38)
<400> 6
atcgacgcgt ccgctcgagc gtcaatgggg cggagttg
38
<210> 7
<211> 36
<212> DNA
<213> Artificial
<220>
<223> artificial sequence
<220>
<221> oligonucleotide
<222> (1)..(36)
<400> 7
ccaggctgca ctcgagacta gttcccacca actcga
<210> 8
<211> 36
<212> DNA
<213> Artificial
<220>
```

.

```
ST98032.ST25.txt
<223> artificial sequence
<220>
<221> oligonucleotide
<222> (1)..(36)
<400> 8
tcgtttgaag cttggaagga gagtagcttc ggtgtc
<210> 9
<211> 30
<212> DNA
<213> Artificial
<220>
<223> artificial sequence
<220>
<221> oligonucleotide
<222> (1)..(30)
<400> 9
cccgttacat aacttacggt aaatggcccg
30
<210> 10
<211> 30
<212> DNA
<213> Artificial
<220>
<223> artificial sequence
<220>
<221> oligonucleotide
<222> (1)..(30)
<400> 10
gggacgcgct tctacaaggc gctggccgaa
```